Department of Epidemiology and Biostatistics, University of California San Francisco, 550 16 St, 2 Fl, San Francisco, CA, 94158, USA.
Monash Bioeth Rev. 2024 Jun;42(1):28-54. doi: 10.1007/s40592-024-00189-z. Epub 2024 Mar 9.
The COVID-19 vaccine has been a miraculous, life-saving advance, offering staggering efficacy in adults, and was developed with astonishing speed. The time from sequencing the virus to authorizing the first COVID-19 vaccine was so brisk even the optimists appear close-minded. Yet, simultaneously, United States' COVID-19 vaccination roll-out and related policies have contained missed opportunities, errors, run counter to evidence-based medicine, and revealed limitations in the judgment of public policymakers. Misplaced utilization, contradictory messaging, and poor deployment in those who would benefit most-the elderly and high-risk-alongside unrealistic messaging, exaggeration, and coercion in those who benefit least-young, healthy Americans-is at the heart. It is important to consider the history of COVID-19 vaccines to identify where we succeeded and where we failed, and the effects that these errors may have more broadly on vaccination hesitancy and routine childhood immunization programs in the decades to come.
新冠病毒疫苗是一项神奇的、拯救生命的进展，在成年人中具有惊人的疗效，并且以惊人的速度开发出来。从对病毒进行测序到批准第一种新冠病毒疫苗，这一时间之短，即使是乐观主义者也显得目光狭隘。然而，与此同时，美国的新冠病毒疫苗接种工作和相关政策也错失了机会，犯了错误，违背了循证医学的原则，并暴露出公共政策制定者判断上的局限性。最需要疫苗的老年人和高危人群未能得到妥善利用、信息相互矛盾、部署不力，而最不需要疫苗的年轻人和健康美国人却得到了不切实际的信息、夸大和强制接种。了解新冠病毒疫苗的历史对于确定我们成功和失败的地方，以及这些错误在未来几十年对疫苗犹豫和常规儿童免疫规划可能产生的更广泛影响非常重要。
